Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Huiren Group
Nanchang, Jiangxi, Chinahuiren.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Huiren Group is an established Chinese pharmaceutical company specializing in the development and commercialization of herbal medicines and small molecule drugs. Its lead products include Liqi Nuanwei Granules for peptic ulcers and Actarit for rheumatoid arthritis, both approved in China. The company also has clinical-stage programs targeting chronic nonatrophic gastritis and stable angina. A phase IV trial is ongoing for Liqinuanwei granule in chronic nonatrophic gastritis.
- Therapeutic areas
- GastroenterologyCardiovascularImmunology
- Modalities
- Herbal medicineSmall molecule drug
- Industry
- Biotech
Beyond the preview
Go deeper on Huiren Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huiren Group.